Loading...

Alpine Immune Sciences

DB:34LA
Snowflake Description

Excellent balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
34LA
DB
$141M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. The last earnings update was 34 days ago. More info.


Add to Portfolio Compare Print
  • Alpine Immune Sciences has significant price volatility in the past 3 months.
34LA Share Price and Events
7 Day Returns
5%
DB:34LA
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-6%
DB:34LA
-10.2%
DE Biotechs
-6%
DE Market
34LA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Alpine Immune Sciences (34LA) 5% 1.1% 28.2% -6% - -
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • 34LA outperformed the Biotechs industry which returned -10.2% over the past year.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

34LA Value

 Is Alpine Immune Sciences undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Alpine Immune Sciences. This is due to cash flow or dividend data being unavailable. The share price is €6.308.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Alpine Immune Sciences's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Alpine Immune Sciences's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:34LA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-2.63
NasdaqGM:ALPN Share Price ** NasdaqGM (2019-04-18) in USD $7.59
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Alpine Immune Sciences.

DB:34LA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:ALPN Share Price ÷ EPS (both in USD)

= 7.59 ÷ -2.63

-2.88x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Alpine Immune Sciences is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Alpine Immune Sciences is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Alpine Immune Sciences's expected growth come at a high price?
Raw Data
DB:34LA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.88x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
-20%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Alpine Immune Sciences, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Alpine Immune Sciences's assets?
Raw Data
DB:34LA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $3.22
NasdaqGM:ALPN Share Price * NasdaqGM (2019-04-18) in USD $7.59
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:34LA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:ALPN Share Price ÷ Book Value per Share (both in USD)

= 7.59 ÷ 3.22

2.36x

* Primary Listing of Alpine Immune Sciences.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Alpine Immune Sciences is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Alpine Immune Sciences's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Alpine Immune Sciences has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

34LA Future Performance

 How is Alpine Immune Sciences expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-20%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Alpine Immune Sciences expected to grow at an attractive rate?
  • Unable to compare Alpine Immune Sciences's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Alpine Immune Sciences's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Alpine Immune Sciences's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:34LA Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:34LA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts -20%
DB:34LA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 56.9%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:34LA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:34LA Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 7 -105 3
2022-12-31 0 -92 3
2021-12-31 0 -75 3
2020-12-31 0 -57 4
2019-12-31 0 -49 5
DB:34LA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 1 -28 -36
2018-09-30 1 -25 -30
2018-06-30 1 -22 -15
2018-03-31 1 -19 -11
2017-12-31 2 -17 -8
2017-09-30 2 -13 -5
2017-06-30 3 -9 -7
2017-03-31 3 -6 -3
2016-12-31 3 -4 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Alpine Immune Sciences is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Alpine Immune Sciences's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:34LA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Alpine Immune Sciences Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:34LA Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -3.61 -2.29 -6.07 3.00
2022-12-31 -3.43 -2.34 -5.50 3.00
2021-12-31 -3.26 -2.39 -4.94 3.00
2020-12-31 -2.85 -1.84 -4.81 4.00
2019-12-31 -2.85 -2.10 -3.74 5.00
DB:34LA Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -2.63
2018-09-30 -2.14
2018-06-30 -1.18
2018-03-31 -1.13
2017-12-31 -1.20
2017-09-30 -1.43
2017-06-30 -10.89
2017-03-31 -7.08
2016-12-31 -2.18

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Alpine Immune Sciences will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Alpine Immune Sciences's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Alpine Immune Sciences has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

34LA Past Performance

  How has Alpine Immune Sciences performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Alpine Immune Sciences's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Alpine Immune Sciences does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Alpine Immune Sciences's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Alpine Immune Sciences's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Alpine Immune Sciences's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Alpine Immune Sciences Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:34LA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.71 -36.49 8.36
2018-09-30 0.83 -29.67 6.86
2018-06-30 0.96 -15.41 6.93
2018-03-31 1.31 -11.10 6.09
2017-12-31 1.73 -7.78 4.58
2017-09-30 2.34 -4.51 3.95
2017-06-30 2.95 -6.82 2.31
2017-03-31 2.95 -3.32 1.52
2016-12-31 2.95 -1.23 1.15
2015-12-31 0.49 -0.37 0.44

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Alpine Immune Sciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Alpine Immune Sciences has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Alpine Immune Sciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Alpine Immune Sciences's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Alpine Immune Sciences has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

34LA Health

 How is Alpine Immune Sciences's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Alpine Immune Sciences's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Alpine Immune Sciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Alpine Immune Sciences's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Alpine Immune Sciences's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 12.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Alpine Immune Sciences Company Filings, last reported 3 months ago.

DB:34LA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 44.59 4.20 52.30
2018-09-30 54.98 4.67 61.98
2018-06-30 66.55 5.12 69.95
2018-03-31 73.88 5.08 76.65
2017-12-31 78.92 5.03 81.24
2017-09-30 82.97 4.99 87.20
2017-06-30 25.48 4.95 31.10
2017-03-31 12.16 0.00 13.57
2016-12-31 10.08 0.11 11.82
2015-12-31 0.26 0.00 5.42
  • Alpine Immune Sciences's level of debt (9.4%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Alpine Immune Sciences's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Alpine Immune Sciences has sufficient cash runway for 1.8 years based on current free cash flow.
  • Alpine Immune Sciences has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 75.7% each year.
X
Financial health checks
We assess Alpine Immune Sciences's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Alpine Immune Sciences has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

34LA Dividends

 What is Alpine Immune Sciences's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Alpine Immune Sciences dividends.
If you bought €2,000 of Alpine Immune Sciences shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Alpine Immune Sciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Alpine Immune Sciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:34LA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:34LA Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Alpine Immune Sciences has not reported any payouts.
  • Unable to verify if Alpine Immune Sciences's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Alpine Immune Sciences's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Alpine Immune Sciences has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Alpine Immune Sciences's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Alpine Immune Sciences afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Alpine Immune Sciences has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

34LA Management

 What is the CEO of Alpine Immune Sciences's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mitch Gold
COMPENSATION $121,439
AGE 50
TENURE AS CEO 2.8 years
CEO Bio

Dr. Mitchell H. Gold, also known as Mitch, M.D., has been Executive Chairman and Chief Executive Officer at Alpine Immune Sciences Inc. since January 2015 and June 2016 respectively. Dr. Gold served as the Executive Chairman, Chief Executive Officer and Assistant Secretary at Nivalis Therapeutics, Inc. since July 24, 2017. He was the Founder and Executive Chairman of Alpine Biosciences, Inc. Dr. Gold was the Founder and Managing Partner of Alpine BioVentures, GP, LLC. He served as the Chief Executive Officer and President of Dendreon Corp. from January 1, 2003 to February 1, 2012. He served as Vice President of Business Development at Dendreon from June 2001 to May 2002 and also served as its Chief Business Officer from May 2002 to December 2002. He served as an Executive Chairman of Dendreon Corp. from January 2012 to June 30, 2012 and served as its Executive Director from May 2002 to February 2013. From April 2000 to May 2001, he served as Vice President of Business Development and Vice President of Sales and Marketing for Data Critical Corporation. He was the Co-Founder of Elixis Corporation and also served as its Chief Executive Officer and President from 1995 to April 2000. Dr. Gold was a Resident Physician in the Department of Urology at the University of Washington. Dr. Gold serves as a Trustee of Cancer Research Institute, Inc. He has been a Director of SillaJen Biotherapeutics, Inc. since April 2012. Dr. Gold serves on the board of the University of Washington/Fred Hutchinson Cancer Research Center Prostate Cancer Institute. For his contributions to science and the treatment of cancer he was named a runner-up for Smartest CEO by Fortune Magazine and was honored with the 2011 Oliver R. Grace Award by the Cancer Research Institute. He was voted Entrepreneur of the Year in the Pacific Northwest in 2011 by Ernst and Young, as well as the top influencer in medicine in 2010 by Seattle Magazine. Dr. Gold was a Urology resident at the University of Washington. He has M.D. from Rush Medical College of Rush University Medical Center in 1993. Dr. Gold also earned a B.S. in Biology from the University of Wisconsin-Madison in 1989.

CEO Compensation
  • Mitch's compensation has been consistent with company performance over the past year.
  • Insufficient data for Mitch to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Alpine Immune Sciences management team in years:

2
Average Tenure
48.5
Average Age
  • The tenure for the Alpine Immune Sciences management team is about average.
Management Team

Mitch Gold

TITLE
Executive Chairman & CEO
COMPENSATION
$121K
AGE
50
TENURE
2.8 yrs

Stanford Peng

TITLE
Executive VP of R&D and Chief Medical Officer
COMPENSATION
$182K
AGE
47
TENURE
2.6 yrs

Mark Litton

TITLE
President & COO
AGE
50
TENURE
0.7 yrs

Paul Rickey

TITLE
Senior VP & CFO
AGE
39
TENURE
2 yrs

Kristine Swiderek

TITLE
Senior Vice President of Research
TENURE
1.3 yrs
Board of Directors Tenure

Average tenure and age of the Alpine Immune Sciences board of directors in years:

2.8
Average Tenure
56
Average Age
  • The average tenure for the Alpine Immune Sciences board of directors is less than 3 years, this suggests a new board.
Board of Directors

Mitch Gold

TITLE
Executive Chairman & CEO
COMPENSATION
$121K
AGE
50
TENURE
4.3 yrs

Jamie Topper

TITLE
Director
AGE
56
TENURE
2.8 yrs

Peter Thompson

TITLE
Director
AGE
58
TENURE
2.8 yrs

Bob Conway

TITLE
Director
AGE
64
TENURE
1.8 yrs

Andy Scharenberg

TITLE
Scientific Advisory Board Chairman

Jay Venkatesan

TITLE
Director
COMPENSATION
$122K
AGE
46
TENURE
2.8 yrs

Paul Sekhri

TITLE
Director
AGE
60
TENURE
1.8 yrs

Manish Butte

TITLE
Member of Scientific Advisory Board

Paul Tumeh

TITLE
Member of Scientific Advisory Board

Chris Peetz

TITLE
Director
AGE
39
TENURE
1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
12. Feb 19 Sell Tiger Management Corp Company 08. Feb 19 08. Feb 19 -25,000 €5.17 €-129,134
23. Jan 19 Buy OrbiMed Advisors, L.L.C. Company 18. Jan 19 18. Jan 19 372,439 €4.73 €1,760,998
23. Jan 19 Buy Alpine BioVentures, GP, LLC Company 18. Jan 19 18. Jan 19 190,875 €4.73 €902,511
22. Jan 19 Buy Patrick Heron Individual 18. Jan 19 18. Jan 19 372,439 €4.73 €1,760,998
20. Aug 18 Sell Deerfield Management Company, L.P. Company 31. Jul 18 17. Aug 18 -222,563 €6.25 €-1,283,490
X
Management checks
We assess Alpine Immune Sciences's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Alpine Immune Sciences has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

34LA News

Simply Wall St News

34LA Company Info

Description

Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer. The company has a collaboration and licensing agreement with the Kite Pharma, Inc. for discovering and developing protein-based immunotherapies targeting the immune synapse to treat cancer. Alpine Immune Sciences, Inc. is headquartered in Seattle, Washington.

Details
Name: Alpine Immune Sciences, Inc.
34LA
Exchange: DB
Founded:
$125,268,904
18,561,029
Website: http://www.alpineimmunesciences.com
Address: Alpine Immune Sciences, Inc.
201 Elliott Avenue West,
Suite 230,
Seattle,
Washington, 98119,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM ALPN Common Stock Nasdaq Global Market US USD 25. Jul 2017
DB 34LA Common Stock Deutsche Boerse AG DE EUR 25. Jul 2017
Number of employees
Current staff
Staff numbers
48
Alpine Immune Sciences employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 22:00
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/03/21
Last earnings filing: 2019/03/18
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.